Efficacy and safety of prednisolone in patients with autoimmune hepatitis

Advances in Therapy

Volumn 23, Issue 1, 2006, Pages 74-91

  Yoneyama, Keiichiro ^a   Honda, Etsuko ^a   Kogo, Mari ^a   Kiuchi, Yuji ^a   Shibata, Minoru ^b   Mitamura, Keiji ^c   Imawari, Michio ^c  

^a SHOWA UNIVERSITY   (Japan)

^b Kanto Teishin Hospital   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse effects; Autoimmune hepatitis; Efficacy; Prednisolone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; GLUCOSE; IMMUNOGLOBULIN G; INSULIN; LACTATE DEHYDROGENASE; ORAL ANTIDIABETIC AGENT; PREDNISOLONE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONVULSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DRUG SAFETY; EUPHORIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INSOMNIA; ISCHEMIA; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MENTAL DISEASE; MOOD DISORDER; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; PARESTHESIA; PEPTIC ULCER; PSYCHOSIS; REFLEX DISORDER; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH PAIN; STOMATITIS; VOMITING;

ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 33646141359     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850349     Document Type: Article

References (30)

1. Mackay IR, Weiden S, Hasker J. Autoimmune hepatitis. Ann NY Acad Sci. 1965;124:767-780.
2. Toda G. Revised criteria for diagnosis of autoimmune hepatitis. Intern Med. 2000;39:999-1000.
3. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan: correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol. 1997;26:1207-1212.
4. Johnson PJ, McFarlane IG. Meeting report. International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005.
5. Czaja AJ, Donaldson PT. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.
6. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
7. Czaja AJ. Autoimmune hepatitis. In: Feldman M, Friedman LS, Sleisenger NH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. Philadelphia, Pa: WB Saunders; 2002:1462-1471.
8. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 1996;334:897-903.
9. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250-259.
10. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci. 1995;40:435-456.
11. Czaja AJ, Beaver S, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92:215-219.
12. Hegarty JE, Noun-Aria KT, Portmann B. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685-689.
13. Onji M, Nonaka T, Horiike N, Moriwaki H, Muto Y, Ohta Y. Present status of autoimmune hepatitis in Japan. Gastroenterol Jpn. 1993;28:134-138.
14. Milkiewics P, Ahmed M, Hathaway M. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver. 1999;19:50-54.
15. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23:116-123.
16. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207-215.
17. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115-123.
18. Blackburn WR, Kaplan HS, McKay DG. Morphologic changes in the developing rat placenta following prednisolone administration. Am J Obstet Gynecol. 1965;92:234-246.
19. Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab. 1985;60:848-854.
20. Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther. 1988;43:354-362.
21. Vermeulen A. The metabolism of 4-14C prednisolone. J Endocrinol. 1959;18:278-291.
22. Bergrem H, Ritland S, Opedal I, Bergan A. Prednisolone pharmacokinetics and protein-binding in patients with portosystemic shunt. Gastroenterology. 1983;18:273-276.
23. Meyer zum Büschenfelde KH, Manns M. Immunological investigations in liver diseases. In: McIntyre N, ed. Oxford Textbook of Clinical Hepatology I. New York, NY: Oxford University Press; 1991:315-320.
24. Thomas HC. Immunologic aspects of liver disease. In: Schiff L, Schiff ER, eds. Diseases of the Liver I. Philadelphia, Pa: Lippincott; 1993:638-658.
25. Yoneyama K, Taniguchi H, Kiuchi Y, Shibata M, Mitamura K. Prognostic index of liver cirrhosis with ascites with and without hepatocellular carcinoma. Scand J Gastroenterol. 2004;39:1272-1279.
26. Yoneyama K, Nebashi Y, Kiuchi Y, Shibata M, Mitamura K. Prognostic index of cirrhotic patients with encephalopathy with and without hepatocellular carcinoma. Dig Dis Sci. 2004;49:1174-1180.
27. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890-897.
28. Takenami T, Sakaguchi K, Nishimura M, et al. Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. Acta Med Okayama. 2001;55:341-347.
29. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension. 1994;23:275-285.
30. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.